Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Graft vs Host Disease 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × axatilimab × Clear all
NCT04710576 2026-03-16

AGAVE-201

Syndax Pharmaceuticals

Phase 2 Active not recruiting
241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT04301778 2026-03-13

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
5 enrolled 13 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡